{"id":"igiv3i-grifols","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Infusion site reactions"},{"rate":null,"effect":"Thromboembolism"},{"rate":null,"effect":"Renal dysfunction"}]},"_chembl":{"chemblId":"CHEMBL513978","moleculeType":"Small molecule","molecularWeight":"372.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IGIV3I Grifols is a human immunoglobulin G (IgG) preparation derived from pooled plasma of multiple donors. It functions through multiple mechanisms including opsonization of pathogens, complement activation, Fc receptor engagement on immune cells, and immune modulation to restore or enhance immune function in immunodeficient or dysregulated states.","oneSentence":"IGIV3I is an intravenous immunoglobulin (IVIG) product that provides passive immunity by delivering pooled human antibodies to modulate immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:27.904Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary immunodeficiency disorders"},{"name":"Secondary immunodeficiency conditions"},{"name":"Autoimmune and inflammatory disorders"}]},"trialDetails":[{"nctId":"NCT00511147","phase":"PHASE3","title":"IGIV Study for Chronic ITP Patients Ages 3-70","status":"COMPLETED","sponsor":"Grifols Biologicals, LLC","startDate":"2008-05","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":64},{"nctId":"NCT00699140","phase":"PHASE3","title":"Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura","status":"COMPLETED","sponsor":"Instituto Grifols, S.A.","startDate":"2008-02","conditions":"Immune (Idiopathic) Thrombocytopenic Purpura","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":154,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IGIV"],"phase":"phase_3","status":"active","brandName":"IGIV3I Grifols","genericName":"IGIV3I Grifols","companyName":"Instituto Grifols, S.A.","companyId":"instituto-grifols-s-a","modality":"Biologic","firstApprovalDate":"","aiSummary":"IGIV3I is an intravenous immunoglobulin (IVIG) product that provides passive immunity by delivering pooled human antibodies to modulate immune responses. Used for Primary immunodeficiency disorders, Secondary immunodeficiency conditions, Autoimmune and inflammatory disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}